Unicycive Therapeutics Inc Cash Flow Conversion Efficiency
Unicycive Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Unicycive Therapeutics Inc (UNCY) has a cash flow conversion efficiency ratio of -0.143x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.60 Million) by net assets ($53.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Unicycive Therapeutics Inc (2018–2025)
Cash flow conversion efficiency of Unicycive Therapeutics Inc from 2018 to 2025. This chart illustrates how Unicycive Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Unicycive Therapeutics Inc (UNCY) stock price for real-time trading data and today's change.
Unicycive Therapeutics Inc Cash Flow Conversion Ratio Explained
Unicycive Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Unicycive Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Unicycive Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Unicycive Therapeutics Inc (UNCY) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AIAI Holdings Corporation Class A Common Stock
NASDAQ:AIAI
|
-0.002x |
|
Sagittarius Life Science
TWO:3205
|
-0.020x |
|
Dekuple
PA:DKUPL
|
0.153x |
|
Technical Olympic S.A
AT:OLYMP
|
-0.002x |
|
I-Berhad
KLSE:4251
|
0.032x |
|
Intech Biopharm Ltd
TWO:6461
|
-0.085x |
|
Pelican Acquisition Corporation Ordinary Shares
NASDAQ:PELI
|
-0.001x |
|
Immunoprecise Antibodies Ltd
NASDAQ:IPA
|
-0.048x |
Annual Cash Flow Conversion Efficiency for Unicycive Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Unicycive Therapeutics Inc from 2018 to 2025. Review financial flexibility index of Unicycive Therapeutics Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $30.20 Million | $-31.32 Million | -1.037x | +73.03% |
| 2024-12-31 | $7.43 Million | $-28.57 Million | -3.845x | -180.11% |
| 2023-12-31 | $-3.81 Million | $-18.28 Million | 4.800x | -85.71% |
| 2022-12-31 | $-466.00K | $-15.65 Million | 33.586x | +9699.95% |
| 2021-12-31 | $16.48 Million | $-5.77 Million | -0.350x | -164.05% |
| 2020-12-31 | $-2.67 Million | $-1.46 Million | 0.546x | -58.94% |
| 2019-12-31 | $-884.00K | $-1.18 Million | 1.330x | +107.01% |
| 2018-12-31 | $-1.21 Million | $-775.00K | 0.643x | -- |
About Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester deriv… Read more